Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.

Dahlke C, Kasonta R, Lunemann S, Krähling V, Zinser ME, Biedenkopf N, Fehling SK, Ly ML, Rechtien A, Stubbe HC, Olearo F, Borregaard S, Jambrecina A, Stahl F, Strecker T, Eickmann M, Lütgehetmann M, Spohn M, Schmiedel S, Lohse AW, Becker S, Addo MM; VEBCON Consortium.

EBioMedicine. 2017 May;19:107-118. doi: 10.1016/j.ebiom.2017.03.045. Epub 2017 Apr 5.

2.

A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?

Lambe T, Bowyer G, Ewer KJ.

Philos Trans R Soc Lond B Biol Sci. 2017 May 26;372(1721). pii: 20160295. doi: 10.1098/rstb.2016.0295. Review.

3.

Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.

Schweneker M, Laimbacher AS, Zimmer G, Wagner S, Schraner EM, Wolferstätter M, Klingenberg M, Dirmeier U, Steigerwald R, Lauterbach H, Hochrein H, Chaplin P, Suter M, Hausmann J.

J Virol. 2017 May 12;91(11). pii: e00343-17. doi: 10.1128/JVI.00343-17. Print 2017 Jun 1.

PMID:
28331098
4.

Global research trends of World Health Organization's top eight emerging pathogens.

Sweileh WM.

Global Health. 2017 Feb 8;13(1):9. doi: 10.1186/s12992-017-0233-9.

5.

Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG.

Pyankov OV, Setoh YX, Bodnev SA, Edmonds JH, Pyankova OG, Pyankov SA, Pali G, Belford S, Lu L, La M, Lovrecz G, Volchkova VA, Chappell KJ, Watterson D, Marsh G, Young PR, Agafonov AA, Farmer JF, Volchkov VE, Suhrbier A, Khromykh AA.

Sci Rep. 2017 Feb 3;7:41537. doi: 10.1038/srep41537.

6.

Complex immune correlates of protection in HIV-1 vaccine efficacy trials.

Tomaras GD, Plotkin SA.

Immunol Rev. 2017 Jan;275(1):245-261. doi: 10.1111/imr.12514. Review.

PMID:
28133811
7.

Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium.

Fan H, Du X, Zhang J, Zheng H, Lu X, Wu Q, Li H, Wang H, Shi Y, Gao G, Zhou Z, Tan DX, Li X.

Sci Rep. 2017 Jan 24;7:41226. doi: 10.1038/srep41226.

8.

IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs.

Boesch AW, Miles AR, Chan YN, Osei-Owusu NY, Ackerman ME.

MAbs. 2017 Apr;9(3):455-465. doi: 10.1080/19420862.2016.1274845. Epub 2017 Jan 5.

PMID:
28055295
9.

Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.

Konduru K, Shurtleff AC, Bradfute SB, Nakamura S, Bavari S, Kaplan G.

PLoS One. 2016 Sep 13;11(9):e0162446. doi: 10.1371/journal.pone.0162446. eCollection 2016.

10.

Ebola vaccines - Where are we?

Watle SV, Norheim G, Røttingen JA.

Hum Vaccin Immunother. 2016 Oct 2;12(10):2700-2703. doi: 10.1080/21645515.2016.1217372.

PMID:
27548643
11.

An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.

Johnson RF, Kurup D, Hagen KR, Fisher C, Keshwara R, Papaneri A, Perry DL, Cooper K, Jahrling PB, Wang JT, Ter Meulen J, Wirblich C, Schnell MJ.

J Infect Dis. 2016 Oct 15;214(suppl 3):S342-S354. Epub 2016 Jul 24.

PMID:
27456709
12.

Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us.

Varkey JB, Ribner BS.

Microbiol Spectr. 2016 Jun;4(3). doi: 10.1128/microbiolspec.EI10-0011-2016.

13.

Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine.

Farooq F, Beck K, Paolino KM, Phillips R, Waters NC, Regules JA, Bergmann-Leitner ES.

Sci Rep. 2016 Jun 21;6:27944. doi: 10.1038/srep27944.

14.

Ebola virus disease candidate vaccines under evaluation in clinical trials.

Martins KA, Jahrling PB, Bavari S, Kuhn JH.

Expert Rev Vaccines. 2016 Sep;15(9):1101-12. doi: 10.1080/14760584.2016.1187566. Epub 2016 May 27.

PMID:
27160784
15.

Ebola virus vaccines - reality or fiction?

Mire CE, Geisbert TW, Feldmann H, Marzi A.

Expert Rev Vaccines. 2016 Nov;15(11):1421-1430. Epub 2016 May 9.

PMID:
27078187
16.

Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection.

Marzi A, Murphy AA, Feldmann F, Parkins CJ, Haddock E, Hanley PW, Emery MJ, Engelmann F, Messaoudi I, Feldmann H, Jarvis MA.

Sci Rep. 2016 Feb 15;6:21674. doi: 10.1038/srep21674.

17.

Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity.

Martins KA, Cooper CL, Stronsky SM, Norris SL, Kwilas SA, Steffens JT, Benko JG, van Tongeren SA, Bavari S.

EBioMedicine. 2015 Nov 27;3:67-78. doi: 10.1016/j.ebiom.2015.11.041. eCollection 2016 Jan.

18.

Antibody therapeutics for Ebola virus disease.

Zeitlin L, Whaley KJ, Olinger GG, Jacobs M, Gopal R, Qiu X, Kobinger GP.

Curr Opin Virol. 2016 Apr;17:45-9. doi: 10.1016/j.coviro.2016.01.006. Epub 2016 Jan 27. Review.

19.

Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans.

Vu H, Shulenin S, Grolla A, Audet J, He S, Kobinger G, Unfer RC, Warfield KL, Aman MJ, Holtsberg FW.

Antiviral Res. 2016 Feb;126:55-61. doi: 10.1016/j.antiviral.2015.11.012. Epub 2015 Dec 8.

20.

Clinical development of Ebola vaccines.

Sridhar S.

Ther Adv Vaccines. 2015 Sep;3(5-6):125-38. doi: 10.1177/2051013615611017. Review.

Supplemental Content

Support Center